Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
76
INDV Quote, Financials, Valuation and Earnings
Last price:
$33.89
Seasonality move
:
4.05%
Day range:
$33.85 - $34.94
52-week range:
$7.62 - $38.00
Dividend yield:
0%
P/E ratio:
33.74x
P/S ratio:
3.63x
P/B ratio:
238.64x
Volume:
1.5M
Avg. volume:
1.8M
1-year change:
276.97%
Market cap:
$4.2B
Revenue:
$1.2B
EPS (TTM):
$1.00
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
INDV
Indivior Pharmaceuticals, Inc.
|
$305.6M | $0.67 | 1.41% | 72.87% | $45.57 |
|
APYX
Apyx Medical Corp.
|
$12.3M | -$0.10 | 8.07% | -17.76% | $6.00 |
|
CRMD
CorMedix, Inc.
|
$94M | $0.52 | 178.58% | 96.01% | $14.86 |
|
FOLD
Amicus Therapeutics, Inc.
|
$185M | $0.18 | 29.62% | 267.32% | $14.50 |
|
NEPH
Nephros, Inc.
|
$4.9M | $0.02 | 15.01% | -69.79% | $6.50 |
|
OWLT
Owlet, Inc.
|
$32M | -$0.06 | 24.19% | -82.16% | $17.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
INDV
Indivior Pharmaceuticals, Inc.
|
$33.89 | $45.57 | $4.2B | 33.74x | $0.00 | 0% | 3.63x |
|
APYX
Apyx Medical Corp.
|
$3.78 | $6.00 | $155.1M | -- | $0.00 | 0% | 3.16x |
|
CRMD
CorMedix, Inc.
|
$7.03 | $14.86 | $553.9M | 3.42x | $0.00 | 0% | 2.37x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.34 | $14.50 | $4.5B | -- | $0.00 | 0% | 7.34x |
|
NEPH
Nephros, Inc.
|
$4.08 | $6.50 | $43.4M | 29.54x | $0.00 | 0% | 2.45x |
|
OWLT
Owlet, Inc.
|
$11.32 | $17.00 | $312.2M | -- | $0.00 | 0% | 1.90x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
INDV
Indivior Pharmaceuticals, Inc.
|
238.93% | 1.419 | 11.83% | 0.73x |
|
APYX
Apyx Medical Corp.
|
87.02% | 4.899 | 48.31% | 3.58x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.679 | 0.48% | 1.60x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.293 | 18.22% | 1.91x |
|
NEPH
Nephros, Inc.
|
10.34% | 3.145 | 2.3% | 3.17x |
|
OWLT
Owlet, Inc.
|
-182.74% | 3.733 | 16.06% | 0.85x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
INDV
Indivior Pharmaceuticals, Inc.
|
$252M | $99M | 130.39% | 14.29% | 31.53% | -$62.4M |
|
APYX
Apyx Medical Corp.
|
$5.1M | -$832K | -29.7% | -146.08% | -6.46% | -$4.1M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
NEPH
Nephros, Inc.
|
$2.9M | $314K | 14.16% | 16.22% | 6.59% | $99K |
|
OWLT
Owlet, Inc.
|
$16.2M | $1.2M | -- | -- | 3.8% | -$2.6M |
Indivior Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns INDV or APYX?
Apyx Medical Corp. has a net margin of 13.38% compared to Indivior Pharmaceuticals, Inc.'s net margin of -15.18%. Indivior Pharmaceuticals, Inc.'s return on equity of 14.29% beat Apyx Medical Corp.'s return on equity of -146.08%.
Company Gross Margin Earnings Per Share Invested Capital INDVIndivior Pharmaceuticals, Inc.80.26% $0.33 $149M APYXApyx Medical Corp.39.65% -$0.05 $45.3M -
What do Analysts Say About INDV or APYX?
Indivior Pharmaceuticals, Inc. has a consensus price target of $45.57, signalling upside risk potential of 34.47%. On the other hand Apyx Medical Corp. has an analysts' consensus of $6.00 which suggests that it could grow by 58.73%. Given that Apyx Medical Corp. has higher upside potential than Indivior Pharmaceuticals, Inc., analysts believe Apyx Medical Corp. is more attractive than Indivior Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INDVIndivior Pharmaceuticals, Inc.5 0 0 APYXApyx Medical Corp.3 1 0 -
Is INDV or APYX More Risky?
Indivior Pharmaceuticals, Inc. has a beta of 1.134, which suggesting that the stock is 13.42% more volatile than S&P 500. In comparison Apyx Medical Corp. has a beta of 1.592, suggesting its more volatile than the S&P 500 by 59.181%.
-
Which is a Better Dividend Stock INDV or APYX?
Indivior Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Apyx Medical Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Indivior Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Apyx Medical Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INDV or APYX?
Indivior Pharmaceuticals, Inc. quarterly revenues are $314M, which are larger than Apyx Medical Corp. quarterly revenues of $12.9M. Indivior Pharmaceuticals, Inc.'s net income of $42M is higher than Apyx Medical Corp.'s net income of -$2M. Notably, Indivior Pharmaceuticals, Inc.'s price-to-earnings ratio is 33.74x while Apyx Medical Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Indivior Pharmaceuticals, Inc. is 3.63x versus 3.16x for Apyx Medical Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INDVIndivior Pharmaceuticals, Inc.3.63x 33.74x $314M $42M APYXApyx Medical Corp.3.16x -- $12.9M -$2M
-
Which has Higher Returns INDV or CRMD?
CorMedix, Inc. has a net margin of 13.38% compared to Indivior Pharmaceuticals, Inc.'s net margin of 49.9%. Indivior Pharmaceuticals, Inc.'s return on equity of 14.29% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital INDVIndivior Pharmaceuticals, Inc.80.26% $0.33 $149M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About INDV or CRMD?
Indivior Pharmaceuticals, Inc. has a consensus price target of $45.57, signalling upside risk potential of 34.47%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 111.34%. Given that CorMedix, Inc. has higher upside potential than Indivior Pharmaceuticals, Inc., analysts believe CorMedix, Inc. is more attractive than Indivior Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INDVIndivior Pharmaceuticals, Inc.5 0 0 CRMDCorMedix, Inc.4 0 0 -
Is INDV or CRMD More Risky?
Indivior Pharmaceuticals, Inc. has a beta of 1.134, which suggesting that the stock is 13.42% more volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.388, suggesting its more volatile than the S&P 500 by 38.76%.
-
Which is a Better Dividend Stock INDV or CRMD?
Indivior Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Indivior Pharmaceuticals, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INDV or CRMD?
Indivior Pharmaceuticals, Inc. quarterly revenues are $314M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Indivior Pharmaceuticals, Inc.'s net income of $42M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Indivior Pharmaceuticals, Inc.'s price-to-earnings ratio is 33.74x while CorMedix, Inc.'s PE ratio is 3.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Indivior Pharmaceuticals, Inc. is 3.63x versus 2.37x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INDVIndivior Pharmaceuticals, Inc.3.63x 33.74x $314M $42M CRMDCorMedix, Inc.2.37x 3.42x $104.3M $108.6M
-
Which has Higher Returns INDV or FOLD?
Amicus Therapeutics, Inc. has a net margin of 13.38% compared to Indivior Pharmaceuticals, Inc.'s net margin of 10.24%. Indivior Pharmaceuticals, Inc.'s return on equity of 14.29% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital INDVIndivior Pharmaceuticals, Inc.80.26% $0.33 $149M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About INDV or FOLD?
Indivior Pharmaceuticals, Inc. has a consensus price target of $45.57, signalling upside risk potential of 34.47%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.12%. Given that Indivior Pharmaceuticals, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Indivior Pharmaceuticals, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INDVIndivior Pharmaceuticals, Inc.5 0 0 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is INDV or FOLD More Risky?
Indivior Pharmaceuticals, Inc. has a beta of 1.134, which suggesting that the stock is 13.42% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.857%.
-
Which is a Better Dividend Stock INDV or FOLD?
Indivior Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Indivior Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INDV or FOLD?
Indivior Pharmaceuticals, Inc. quarterly revenues are $314M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Indivior Pharmaceuticals, Inc.'s net income of $42M is higher than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Indivior Pharmaceuticals, Inc.'s price-to-earnings ratio is 33.74x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Indivior Pharmaceuticals, Inc. is 3.63x versus 7.34x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INDVIndivior Pharmaceuticals, Inc.3.63x 33.74x $314M $42M FOLDAmicus Therapeutics, Inc.7.34x -- $169.1M $17.3M
-
Which has Higher Returns INDV or NEPH?
Nephros, Inc. has a net margin of 13.38% compared to Indivior Pharmaceuticals, Inc.'s net margin of 7.07%. Indivior Pharmaceuticals, Inc.'s return on equity of 14.29% beat Nephros, Inc.'s return on equity of 16.22%.
Company Gross Margin Earnings Per Share Invested Capital INDVIndivior Pharmaceuticals, Inc.80.26% $0.33 $149M NEPHNephros, Inc.60.47% $0.03 $11.2M -
What do Analysts Say About INDV or NEPH?
Indivior Pharmaceuticals, Inc. has a consensus price target of $45.57, signalling upside risk potential of 34.47%. On the other hand Nephros, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 59.31%. Given that Nephros, Inc. has higher upside potential than Indivior Pharmaceuticals, Inc., analysts believe Nephros, Inc. is more attractive than Indivior Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INDVIndivior Pharmaceuticals, Inc.5 0 0 NEPHNephros, Inc.1 0 0 -
Is INDV or NEPH More Risky?
Indivior Pharmaceuticals, Inc. has a beta of 1.134, which suggesting that the stock is 13.42% more volatile than S&P 500. In comparison Nephros, Inc. has a beta of 1.397, suggesting its more volatile than the S&P 500 by 39.715%.
-
Which is a Better Dividend Stock INDV or NEPH?
Indivior Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nephros, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Indivior Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Nephros, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INDV or NEPH?
Indivior Pharmaceuticals, Inc. quarterly revenues are $314M, which are larger than Nephros, Inc. quarterly revenues of $4.8M. Indivior Pharmaceuticals, Inc.'s net income of $42M is higher than Nephros, Inc.'s net income of $337K. Notably, Indivior Pharmaceuticals, Inc.'s price-to-earnings ratio is 33.74x while Nephros, Inc.'s PE ratio is 29.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Indivior Pharmaceuticals, Inc. is 3.63x versus 2.45x for Nephros, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INDVIndivior Pharmaceuticals, Inc.3.63x 33.74x $314M $42M NEPHNephros, Inc.2.45x 29.54x $4.8M $337K
-
Which has Higher Returns INDV or OWLT?
Owlet, Inc. has a net margin of 13.38% compared to Indivior Pharmaceuticals, Inc.'s net margin of 12.58%. Indivior Pharmaceuticals, Inc.'s return on equity of 14.29% beat Owlet, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital INDVIndivior Pharmaceuticals, Inc.80.26% $0.33 $149M OWLTOwlet, Inc.50.51% $0.13 -$13.7M -
What do Analysts Say About INDV or OWLT?
Indivior Pharmaceuticals, Inc. has a consensus price target of $45.57, signalling upside risk potential of 34.47%. On the other hand Owlet, Inc. has an analysts' consensus of $17.00 which suggests that it could grow by 50.18%. Given that Owlet, Inc. has higher upside potential than Indivior Pharmaceuticals, Inc., analysts believe Owlet, Inc. is more attractive than Indivior Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INDVIndivior Pharmaceuticals, Inc.5 0 0 OWLTOwlet, Inc.5 0 0 -
Is INDV or OWLT More Risky?
Indivior Pharmaceuticals, Inc. has a beta of 1.134, which suggesting that the stock is 13.42% more volatile than S&P 500. In comparison Owlet, Inc. has a beta of 1.713, suggesting its more volatile than the S&P 500 by 71.275%.
-
Which is a Better Dividend Stock INDV or OWLT?
Indivior Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Owlet, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Indivior Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Owlet, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INDV or OWLT?
Indivior Pharmaceuticals, Inc. quarterly revenues are $314M, which are larger than Owlet, Inc. quarterly revenues of $32M. Indivior Pharmaceuticals, Inc.'s net income of $42M is higher than Owlet, Inc.'s net income of $4M. Notably, Indivior Pharmaceuticals, Inc.'s price-to-earnings ratio is 33.74x while Owlet, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Indivior Pharmaceuticals, Inc. is 3.63x versus 1.90x for Owlet, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INDVIndivior Pharmaceuticals, Inc.3.63x 33.74x $314M $42M OWLTOwlet, Inc.1.90x -- $32M $4M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
